01 August 2019
Visiongain has launched a new pharma report Global Rare Disease Drugs Market Report: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.
The global rare disease drugs market is one that is driven by innovation which is vital for maintaining the rich pipeline of rare diseases drugs seen in the market today. There is an increasing focus to identify and treat rare diseases that currently are undertreated which creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market.
The lead analyst of the report commented "It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge. As a result, rare diseases lack published data on long-term outcomes of treatment and are often characterized incompletely. This requires exploring international and regional research partnerships, collaborating with doctors working on any rare disease, and with patient groups and families dealing with the consequences of these disorders."
Leading companies featured in the report AbbVie, Bristol-Myers Squibb (BMS), Celgene, Merck & Co., Inc., Novartis, Pfizer, Roche, Sanofi, Takeda, Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.